2-Ethyl-3-methoxypyrazine
Common Name: |
2-Ethyl-3-methoxypyrazine |
IUPAC Name: |
2-ethyl-3-methoxypyrazine |
Molecular Formula: |
C8H12N2O |
SMILES: |
CCC1=NC=CN=C1OC |
Inchi: |
1S/C7H10N2O/c1-3-6-7(10-2)9-5-4-8-6/h4-5H,3H2,1-2H3 |
Inchi Key: |
DPCILIMHENXHQX-UHFFFAOYSA-N |
Cas No: |
25680-58-4 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
1 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
152.19 |
Mass (g/mol) |
138.079 |
Molar Refractivity |
43.10 |
Net Charge |
|
HBD |
|
HBA |
3 |
Rt Bonds |
2 |
Rings |
1 |
TPSA |
35.01 |
Hetero Atoms |
3 |
Heavy Atoms |
11 |
Aromatic Heavy Atoms |
6 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
90.00 @ 40.00 mm Hg |
Vapor Pressure (mmHg@25.00 °C) |
1.577 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.50 |
LogP |
1.048 |
iLOGP |
2.16 |
XLOGP3 |
2.00 |
WLOGP |
1.61 |
MLOGP |
0.34 |
ESOL Log S |
-2.32 |
ESOL Solubility (mg/ml) |
0.736 |
ESOL Solubility (mol/l) |
0.005 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-2.36 |
Ali Solubility (mg/ml) |
0.66 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-2.59 |
Silicos-IT Solubility (mg/ml) |
0.4 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.81 |
Bioavailability Score |
0.55 |
Caco2 |
0 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.699 |
CYP1A2 Inhibitor |
1 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.042 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |